Latest Sensorium Therapeutics News & Updates

See the latest news and media coverage for Sensorium. We track all announcements, press releases, and industry mentions in real time, all in one place.

Sensorium Therapeutics (Sensorium)

Clinical-stage biotechnology company developing nature-derived CNS therapies

sensorium.bio

Headquarters: Boston, United States
Founded year: 2021
Company type: Private company
Number of employees: 25–50
Industry: Pharmaceuticals

Last updated October 15

Latest news about Sensorium Therapeutics (Sensorium)

In short: Sensorium advanced its lead anxiety candidate SNTX-2643 with FDA IND clearance, positive Phase 1a data, and a $25M Series A raise.

Company announcements

October 15 Sensorium

Sensorium appoints Charles Nemeroff to advisory board

Dr. Nemeroff joins to guide clinical testing of SNTX-2643, a differentiated serotonin transporter mechanism for brain and mental health conditions.

October 8 Sensorium

Sensorium welcomes Stephen Brannan as advisor

The former Karuna CMO joins to guide Sensorium’s neuroscience pipeline, building on Phase 1a anxiety data.

August 19 Sensorium

Sensorium reports positive Phase 1a data for SNTX-2643

The drug showed rapid CNS activity and safety in healthy volunteers. Data were presented at Psych Congress 2026.

8 July 2025 Sensorium

Sensorium receives FDA IND clearance for SNTX-2643

The first-in-class anxiolytic is a precision serotonin modulator, with first-in-human dosing in Q3 2025.

Media coverage

September 21 Yahoo Finance

Sensorium Therapeutics Announces Positive Phase 1a Data for SNTX-2643 Showing Rapid and Sustained CNS Pharmacodynamic Activity

Sensorium Therapeutics, a clinical-stage central nervous system (CNS) biotechnology company developing mechanistically novel small-molecule medicines for psychiatric and neurological disorders, today announced positive results from...

May 27 Morningstar

Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026

Company also announces appointment of Cole Brown, M.D., as Chief Medical Officer and formation of a Clinical Advisory Board CAMBRIDGE, Mass., May 27, 2026 /PRNewswire...

29 August 2025 Finsmes

Sensorium Therapeutics Raises $25M in Series A Funding

Sensorium Therapeutics, a Boston, MA-based neuroscience therapeutics company, raised $25m in Series A funding...

8 July 2025 Yahoo Finance

Sensorium Therapeutics Receives FDA IND Clearance for SNTX-2643, a First-in-Class, Rapid-Acting Anxiolytic

BOSTON, July 8, 2025 /PRNewswire/ -- Sensorium Therapeutics, Inc. (Sensorium), a neuroscience therapeutics company inspired by nature and guided by human biology to transform mental...

Never miss news about Sensorium

Track Sensorium and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Sensorium competitors & trending companies

Browse news for competitors to Sensorium and other trending companies.